lymphoproliferative

lymphoproliferative

 [lim″fo-pro-lif´er-ah″tiv]
pertaining to or characterized by proliferation of lymphoid tissue.
lymphoproliferative disorders a group of malignant neoplasms arising from cells related to the common multipotential, primordial lymphoreticular cell that includes among others the lymphocytic, histiocytic, and monocytic leukemias, multiple myeloma, plasmacytoma, Hodgkin's disease, all lymphocytic lymphomas, and immunosecretory disorders associated with monoclonal gammopathy. An interrelationship with the myeloproliferative disorders is thought to exist.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.
References in periodicals archive ?
Atara's pipeline includes tab-cel (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies.
Atara Biotherapeutics announced an updated development plan for the Phase 3 tab-cel program for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease.
Autologous Peripheral Blood Stem Cell Transplantation Among Lymphoproliferative Disease Patients: Factors Influencing Engraftment.
The United States Food and Drug Administration (FDA) has granted Orphan Drug Designations (ODD) to United States-based Viracta Therapeutics, Incorporated's Phase two drug candidate, nanatinostat, in combination with the antiviral valganciclovir intended for the treatment of post-transplant lymphoproliferative disorder (PTLD), plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma, it was reported yesterday.
INDOLENT T-CELL LYMPHOPROLIFERATIVE DISORDER OF THE GI TRACT
Factors that appeared unlinked with PTAA included acute organ rejection, duration of post-transplantation steroidal treatment, organ type (living versus cadaveric), donor/recipient blood type and compatibility, infections besides Epstein-Barr virus, and posttransplant lymphoproliferative disease.
Post-transplant lymphoproliferative disease (PTLD) is a significant complication of pediatric solid-organ transplantation, with a reported incidence of 6%-20% and a mortality rate of 12%-60% (1-3).
It belongs to the spectrum of primary cutaneous CD30+ lymphoproliferative disorders, along with primary cutaneous anaplastic large cell lymphoma (primary C-ALCL) with which it shares overlapping clinical and histopathologic features.
Alpha HCD typically affects the gastrointestinal system, whereas y HCD has a heterogeneous clinical presentation, ranging from an asymptomatic state to aggressive lymphoproliferative process (1).
After 6 years, the cystic lung lesions gradually enlarged and increased in number (Figure 3), but she remained to have no respiratory symptoms, no decrease in FEV1 (1.18 L), and no findings of lymphoproliferative disorder.